Hepatorenal syndrome is treated primarily with vasoconstrictors and intravenous albumin, though liver transplantation remains the only therapy that resolves the underlying problem. HRS develops when severe liver disease triggers widening of blood vessels in the gut, which starves the kidneys of adequate blood flow and causes them to shut down despite being structurally intact. The treatment landscape shifted meaningfully in the early 2020s when terlipressin gained regulatory traction in North America, but the story is more complicated than a single drug approval suggests, and much of the treatment strategy revolves around buying time until a transplant becomes available.
Why HRS Happens and Why That Shapes Treatment
Understanding HRS treatment starts with one key concept: the kidneys themselves are not damaged. In advanced cirrhosis, rising pressure in the portal vein causes blood vessels in the gut and surrounding organs to dilate dramatically. Nitric oxide is one of the main drivers of this vasodilation, though the process involves multiple signaling molecules and no single one is entirely responsible.1PubMed Central. Physiopathology of splanchnic vasodilation in portal hypertension Blood pools in the splanchnic (gut) circulation, and the body compensates by constricting blood vessels elsewhere, including in the kidneys. As this worsens, the kidneys receive so little blood flow that they essentially stop filtering.
This is why the worsening of splanchnic vasodilation appears to directly drive kidney failure in cirrhosis. Studies of cirrhotic patients have found that as the hyperdynamic circulation intensifies, blood flow to non-gut territories drops, and renal function deteriorates.2Hepatology. Splanchnic vasodilation and renal vasoconstriction: A key to the hepatorenal syndrome? Because the kidneys are functionally impaired rather than structurally destroyed, the damage is potentially reversible if blood flow can be restored. That reversibility is what makes medical treatment worth pursuing, and it explains why the entire pharmacological strategy centers on constricting gut blood vessels to redirect flow back to the kidneys.
Vasoconstrictors Plus Albumin as First-Line Treatment
The standard approach combines a vasoconstrictor drug with intravenous albumin. The vasoconstrictor tightens the dilated splanchnic vessels, while albumin expands blood volume and helps maintain adequate circulating pressure. Together, they aim to improve kidney perfusion enough that filtration resumes.
Terlipressin, a synthetic vasopressin analogue, is the most studied drug for this purpose. In a randomized trial comparing terlipressin plus albumin against albumin alone, kidney function improved in about 44% of patients receiving the combination, versus roughly 9% of those getting albumin by itself.3PubMed. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study That trial also identified baseline urine output, creatinine level, and white blood cell count as factors predicting who would respond.
The CONFIRM trial, a large North American randomized study, confirmed that terlipressin produced higher rates of HRS reversal than placebo.4PubMed. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward However, the FDA initially declined to approve terlipressin due to safety concerns, particularly around respiratory adverse events and the absence of a clear mortality benefit. The drug was ultimately approved in the United States in 2022 with a boxed warning, but this cautious regulatory path tells you something important about the treatment: terlipressin reliably improves kidney numbers, yet whether that translates to people living longer outside the context of transplant remains an open question.
The Safety Profile That Almost Derailed Approval
Terlipressin’s side-effect profile deserves its own discussion because it directly affects treatment decisions. In the CONFIRM trial, death within 90 days from respiratory causes occurred in about 11% of patients receiving terlipressin compared with 2% in the placebo group.5PubMed. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome Other common adverse events included abdominal pain, nausea, and diarrhea. These respiratory complications are thought to relate to the drug’s effects on fluid balance. Terlipressin increases the volume of blood returning to the heart, and in patients who already have fluid overload or compromised lung function, that extra volume can push them into respiratory failure.
Clinicians now screen patients more carefully before starting terlipressin, watching for signs of volume overload, low oxygen levels, or existing lung disease. The drug is generally avoided in patients on mechanical ventilation or those with significant baseline respiratory compromise. Getting the fluid balance right, including judicious use of albumin, appears to be critical for reducing the risk of serious pulmonary events.
Norepinephrine as an Alternative Vasoconstrictor
Outside North America, norepinephrine (noradrenaline) has been widely used for HRS, partly because terlipressin was historically unavailable in the United States and partly because norepinephrine is dramatically cheaper. A head-to-head randomized study found that HRS reversed in about 39% of patients on norepinephrine and about 43% on terlipressin, with no statistically significant difference in reversal rates or short-term survival.6PubMed. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study That study also noted norepinephrine was significantly less expensive.
Meta-analyses comparing the two drugs reinforce this picture. One pooled analysis found a numerically higher HRS reversal rate with terlipressin but with wide confidence intervals and no statistical significance.7PubMed Central. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis Terlipressin tended to cause gut-related side effects like diarrhea and abdominal pain, while norepinephrine was associated more with cardiovascular events like chest pain. A separate meta-analysis of nine studies found no significant difference in HRS reversal rates or mortality between the two drugs, though norepinephrine-treated patients showed slightly higher creatinine clearance.8PubMed. Efficacy and safety of terlipressin and albumin vs. noradrenaline and albumin in adult patients with hepatorenal syndrome: A systematic review and meta-analysis
The practical tradeoff comes down to logistics. Norepinephrine requires an ICU setting with continuous monitoring and a central venous catheter. Terlipressin can be given as intermittent intravenous boluses or a continuous infusion, potentially allowing treatment outside the ICU. Where resources and ICU beds are limited, norepinephrine’s lower cost can be a deciding factor. Where outpatient or ward-level treatment is preferred, terlipressin has the logistical edge.
Midodrine and Octreotide for Settings Without Vasopressin Analogues
Before terlipressin was available in the United States, the most common approach was a triple combination of midodrine (an oral vasoconstrictor), octreotide (which reduces splanchnic blood flow), and albumin. A retrospective study found that this triple therapy improved transplant-free survival considerably compared to no treatment, with median survival stretching to about 101 days versus 18 days in untreated patients.9PubMed. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome
However, when directly compared to terlipressin in a randomized trial, the midodrine-octreotide combination fell well short. Kidney function recovered in about 70% of patients receiving terlipressin versus roughly 29% of those on midodrine-octreotide.10PubMed. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial A real-world comparison using data from the United Kingdom (where terlipressin was standard) and the United States (where midodrine-octreotide predominated) found similar results: HRS reversed in about 53% of terlipressin-treated patients compared with roughly 17% of those on midodrine-octreotide.11Clinical and Translational Gastroenterology. Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury
Midodrine-octreotide remains relevant for patients who cannot tolerate terlipressin or norepinephrine, and it may still be the default in hospitals that have not yet integrated terlipressin into their protocols. But the evidence gap is large enough that guidelines increasingly position it as a second-tier option.
When Drug Therapy Fails
Not everyone responds to vasoconstrictors. When pharmacological treatment does not improve kidney function, the next steps involve bridging strategies to keep the patient alive and their internal chemistry manageable until a liver transplant can happen. Kidney replacement therapy, essentially dialysis, is used to handle fluid overload, dangerous electrolyte shifts, and the buildup of waste products the kidneys can no longer clear.12Therapeutic Advances in Gastroenterology. Management of hepatorenal syndrome in liver cirrhosis: a recent update It does not fix HRS, but it can sustain the patient through the waiting period.
The evidence on dialysis outcomes in HRS is sobering. One study found that among HRS patients receiving hemodialysis, 30-day survival was only about 27%. Crucially, none of the patients who also required mechanical ventilation survived past 30 days, while roughly half of those not on a ventilator did.13Journal of Gastroenterology and Hepatology. Which patients benefit from hemodialysis therapy in hepatorenal syndrome? That finding suggests dialysis may be a reasonable bridge for patients who are not yet critically ill, but it becomes ineffective once multi-organ failure sets in.
TIPS as an Interventional Option
A transjugular intrahepatic portosystemic shunt, or TIPS, is a procedure that creates a channel inside the liver to reroute blood flow and reduce portal pressure. By lowering the pressure driving splanchnic vasodilation, TIPS addresses the root hemodynamic problem. Available evidence suggests TIPS frequently improves kidney function in patients with portal hypertension, including those with HRS, and no studies have shown persistent worsening of kidney function after the procedure.14PubMed Central. Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review
In practice, though, TIPS has a limited role in HRS management. Many HRS patients have liver function so poor that they cannot safely tolerate the procedure, which carries a risk of worsening hepatic encephalopathy and liver failure. TIPS tends to be considered for patients with relatively preserved liver function who have not responded adequately to drug therapy, or for those whose HRS is developing in the context of refractory ascites that TIPS would treat simultaneously.
Liver Transplantation as Definitive Treatment
Liver transplantation is the only treatment that resolves HRS by correcting the underlying liver disease. Once a healthy liver is in place, the hemodynamic cascade that caused the kidneys to fail reverses. In one study of liver transplant recipients who had HRS beforehand, the syndrome resolved in 58% of patients, with the average time to resolution around three weeks, though it ranged from four days to over three months.15PubMed Central. The course of type 1 hepato-renal syndrome post liver transplantation Even patients who had been on dialysis before transplant saw recovery, with half of those whose HRS resolved having been dialysis-dependent beforehand.
More recent data tracking kidney function after liver transplant found that HRS patients showed meaningful improvement in estimated kidney filtration rate by three months post-transplant, stabilizing at around 51 mL/min at one year.16American Journal of Transplantation. Renal Recovery and Long-Term Outcomes in Hepatorenal Syndrome and Chronic Kidney Disease After Liver Transplantation That number is below normal but represents a significant recovery from the near-shutdown state of active HRS.
A persistent clinical challenge is deciding who needs a combined liver-kidney transplant versus a liver transplant alone. The difficulty lies in distinguishing HRS, which should reverse after a liver transplant, from structural kidney damage that will not recover. Studies have struggled to identify reliable preoperative factors that predict whether the kidneys will bounce back.17PubMed. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant The criteria for simultaneous liver-kidney allocation remain particularly messy for patients with acute kidney injury, largely because of this inability to confidently separate HRS from intrinsic kidney disease at the bedside.18PubMed. Simultaneous liver kidney transplantation
Telling HRS Apart from Other Kidney Injuries
The distinction between HRS and other forms of acute kidney injury in cirrhotic patients is not just academic. It directly determines treatment. If the kidneys are failing because of structural damage (a condition called acute tubular necrosis, or ATN), vasoconstrictors will not help, and the treatment strategy shifts entirely toward dialysis or transplant planning. If it is HRS, drug therapy has a real shot at reversing the problem.
Traditional diagnosis relied on excluding other causes, essentially a process of ruling out infections, drugs that damage the kidneys, and fluid depletion. Newer urinary biomarkers are making this easier. A protein called NGAL (neutrophil gelatinase-associated lipocalin) is released when kidney tubule cells are physically injured. In a prospective study of cirrhotic patients with acute kidney injury, urinary NGAL levels were markedly higher in those with ATN than in those with HRS or simple dehydration-related kidney problems, and at an optimal cutoff, NGAL distinguished ATN from other causes with reasonable accuracy.19PubMed Central. Urinary NGAL as a Diagnostic and Prognostic Marker for Acute Kidney Injury in Cirrhosis: A Prospective Study Other markers like interleukin-18, kidney injury molecule-1, and liver-type fatty acid binding protein have also shown differences between structural and functional kidney injury in cirrhosis.20Hepatology. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury
These biomarkers are not yet part of standard diagnostic criteria, but they are being actively incorporated into proposed classification systems. A 2023 joint meeting of the International Club of Ascites and the Acute Disease Quality Initiative worked to develop updated diagnostic criteria for HRS and highlighted the need for better tools to distinguish HRS from other causes of kidney injury in cirrhosis.21PubMed Central. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
Preventing HRS Before It Starts
Some of the most impactful interventions for HRS happen before the syndrome develops. Two scenarios carry well-documented risk, and both have evidence-based preventive strategies.
The first is spontaneous bacterial peritonitis (SBP), an infection of the fluid in the abdomen that is common in advanced cirrhosis. A landmark trial showed that adding intravenous albumin to antibiotic therapy during SBP episodes reduced kidney impairment from 33% to 10% and also lowered mortality.22PubMed. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis This benefit appears most pronounced in higher-risk patients, specifically those with elevated bilirubin, elevated blood urea nitrogen, or elevated creatinine at the time of infection.23PubMed Central. Should albumin be used in all patients with spontaneous bacterial peritonitis? Albumin during SBP is now considered standard of care in guidelines worldwide.
The second high-risk scenario is large-volume paracentesis, where several liters of ascitic fluid are drained from the abdomen. Removing that much fluid quickly can trigger a circulatory collapse called paracentesis-induced circulatory dysfunction (PICD), which can lead to kidney impairment and further hemodynamic deterioration. Albumin infusion during large-volume paracentesis prevents PICD more effectively than saline; one trial found PICD in about 11% of patients receiving albumin versus 33% of those receiving saline.24PubMed. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites When less than about six liters are drained, saline appears to be an acceptable alternative. For smaller-volume procedures, oral midodrine has also shown promise as an albumin substitute in some settings.25PubMed Central. Midodrine versus Albumin to Prevent Paracentesis Induced Circulatory Dysfunction in Acute on Chronic Liver Failure Patients in the Outpatient Clinic–a Randomized Controlled Trial
Cost and Access Realities
HRS treatment costs are staggering, and the choice of drug has enormous financial implications. A cost-effectiveness analysis from the U.S. hospital perspective estimated the cost per complete response at roughly $452,000 for terlipressin plus albumin, compared to about $931,000 for norepinephrine plus albumin and nearly $5 million for midodrine-octreotide plus albumin.26PubMed. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective These numbers reflect U.S. hospital economics, where terlipressin’s higher drug cost is offset by its substantially higher response rate and the ability to deliver it outside the ICU. The midodrine-octreotide combination’s low response rate makes it the most expensive option per success, despite the drugs themselves being cheap.
Globally, the picture looks different. In countries where norepinephrine is the default and ICU costs are lower, norepinephrine remains the practical choice for many hospitals. Terlipressin availability is still uneven across health systems, and for patients in regions without access to either drug, the only remaining options are dialysis as a bridge and expedited transplant listing, both of which depend on infrastructure that is far from universal.
HRS in Children
Pediatric HRS follows the same basic pathophysiology as in adults, with splanchnic vasodilation and renal vasoconstriction driving kidney failure. Treatment recommendations parallel the adult approach: vasoconstrictors, primarily terlipressin, combined with albumin as first-line therapy, with kidney replacement therapy and extracorporeal liver support as bridges to transplant when drugs fail.27PubMed Central. Hepatorenal syndrome in children: a review The pediatric literature is thin compared to adults, largely because HRS is less common in children and randomized trials in this population barely exist. Dosing and monitoring are extrapolated from adult data, which means clinicians managing pediatric HRS are operating with more uncertainty than they would like.